PGC would not be the only Company with impairment write offs in FY20.
The addressable market in their continuing operations leaves plenty of room for growth. It was a little disappointing they were not able to capitalise more on "essential products supply" during FY20. Not sure if this was systems related, supply chain related or something else.
The Company is only targeting >5% revenue growth per year. This will take them a long time to achieve their target of "70% of medical and surgical supplies segment"
As for dividend payments, I guess they will make a decision when FY21 results start shaping up.
Paying down debt is good, they have a fairly low interest rate (2.22%-2.79%). I understand everyone's concern though with the bank loan of $76m comprising a large portion of net assets. Looking into this some more, $75m of this has a maturity of between 2 to 6 years...so there is some flexibility.
Cheers, Wolf
PGC Price at posting:
20.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)